Editor: What To Know
- “ÅKRN is a wonderful partner for NAMSA—I feel we have a perfect fit surrounding company values and a team that shares the same drive to provide exceptional service and resources to the medical device and diagnostic industries,” commented Dr.
- As the global leader in the medical device testing industry since 1967, NAMSA also provides Sponsors support in the areas of regulatory, reimbursement, quality, and clinical research services.
- ÅKRN, founded in 2018, focuses on providing exceptional clinical and regulatory services to the medical device and diagnostic industries in Europe.
NAMSA, a world leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, announced today its intent to acquire ÅKRN Scientific Consulting, a prominent European Medical Device CRO based in Madrid, Spain.
ÅKRN, founded in 2018, focuses on providing exceptional clinical and regulatory services to the medical device and diagnostic industries in Europe. Grounded in medicine and science, the organization assists Sponsors move MedTech products from medical discovery into clinical development, commercialization and Post-Market Follow-Up. Known for their expertise in Cardiovascular research, ÅKRN’s Team of Clinical Scientists and Project Managers serve as trusted Client Advisors throughout the complete clinical development process via diligent planning and superior execution.
“We are thrilled to welcome ÅKRN to NAMSA,” said Dr. Christophe Berthoux, CEO of NAMSA. “The organization is well-respected for their proficiency in European medical device regulations and providing exceptional clinical support to MedTech Sponsors. Adding them to our team will expand our depth of expertise, enabling us to meet the growing demand for safe, efficient clinical development and commercialization of life-changing medical products,” Dr. Berthoux concluded.
As the global leader in the medical device testing industry since 1967, NAMSA also provides Sponsors support in the areas of regulatory, reimbursement, quality, and clinical research services. NAMSA’s full continuum development services helps Clients overcome development hurdles, mitigate concerns and streamline commercialization efforts. Through proactive planning of varying global regulatory requirements and clinical research obligations, NAMSA’s services are proven to accelerate time-to-market and lower development costs up to 50 percent over industry averages.
“ÅKRN is a wonderful partner for NAMSA—I feel we have a perfect fit surrounding company values and a team that shares the same drive to provide exceptional service and resources to the medical device and diagnostic industries,” commented Dr. Maria Nyåkern, ÅKRN CEO. “Our team, strongly grounded in medicine and science, looks forward to partnering with NAMSA as we continue to increase our presence globally and in Europe. With the expanded expertise of our combined organizations, we will serve as the world’s leading CRO for Cardiovascular research services,” Dr. Nyåkern concluded.
The acquisition of ÅKRN increases NAMSA’s global scale, now serving MedTech Clients across 19 locations throughout APAC, Europe, North America and South America.
